March 6 Endo Health Solutions Inc said
the U.S. Food and Drug Administration approved its
thrice-rejected testosterone drug, Aveed, to treat male
The health regulator rejected the drug last May, saying that
Endo needed a better plan to manage the risks associated with
Aveed, which contains testosterone and castor oil, is
expected to be launched in early March, Endo said on Thursday.
Male hypogonadism is a condition characterized by low
production of the hormone testosterone, often leading to a loss
of libido, depression and fatigue.
(Reporting by Natalie Grover and Vrinda Manocha in Bangalore;
Editing by Kirti Pandey)